(Q38088262)

28 August 2017

title

Polycythemia vera: current pharmacotherapy and future directions (English)

1 reference

28 August 2017

0 references

1 reference

Benjamin Hensley

1

1 reference

28 August 2017

Holly Geyer

series ordinal

2

1 reference

28 August 2017

Ruben Mesa

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

609-617

1 reference

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

The haematocrit and platelet target in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Cerebral blood-flow in polycythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Cardiovascular events and intensity of treatment in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

The renaissance of interferon therapy for the treatment of myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.779671

10.1517/14656566.2013.779671

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference